DNA may hold secret for feline HCM therapiesAugust 6, 2021The effectiveness of a commonly prescribed treatment for hypertrophic cardiomyopathy (HCM) in cats may vary depending on the animal’s genes.
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
NYC Animal Medical Center leads global feline cardiovascular risk studyMay 21, 2018NYC's Animal Medical Center (AMC) announced the publication of a research study that identifies how hypertrophic cardiomyopathy—a form of heart disease that can cause sudden death and heart failure in people—is also present in cats and linked to serious health problems in these pets. Termed "The Reveal Study," the collaborative, international, 10-year investigation involved 50 veterinary centers in 21 countries in an effort to learn how this disease impacts the health of cats over more than a decade.1 Published in the Journal of Veterinary Internal Medicine, lead author, Philip Fox, DVM, MS, DACVIM/ECVIM (Cardiology), DACVECC, is head of cardiology at the Animal Medical Center and director of its Caspary Research Institute. The study reports that hypertrophic cardiomyopathy is a global feline health problem and estimates that it might affect millions of pet cats. Although the disease has been known by veterinarians for nearly 50 years, almost nothing was known about its epidemiology until now. "The Reveal Study documented that hypertrophic cardiomyopathy puts cats at considerable risk to develop congestive heart failure, arterial blood clots, and cardiac death," said Dr. Fox. "Heart failure or blood clots occur in nearly one-third of affected cats, and overall, one in every three or …
